BioSpace News Archive

Nasus Pharma Ltd announced positive results from a pilot trial of intranasal powder-based Epinephrine.

GT Biopharma, Inc.announced Jeffrey S. Miller, M.D., Deputy Director of the Masonic Cancer Center and Consulting Chief Scientific Officer, provided an update concerning GTB-3550 TriKE.

Stratus™ Medical, a company focused on advancing radiofrequency (RF) ablation treatment for chronic pain, announced today it received CE Mark (Conformité Européenne) for Nimbus® RF Multitined Expandable Electrode and Vesta™ RF Cannula.

HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced the regulatory approval for HBI-8000 monotherapy of relapsed or refractory (R/R) adult T-cell leukemia/lymphoma (ATL) by the Japanese Pharmaceuticals and Medical Devices Agency.

Tvardi Therapeutics, Inc. has closed a $74 million Series B financing.

Addressing some of the most time-consuming challenges of biopharma companies in building clinical studies and rolling out drug trials, Anju Software has launched TrialMaster 5.1, a software platform with a range of enhanced trial efficiency capabilities, highlighted by a unique company-created technology called Parameterized Edit Check that facilitates reuse of edit checks for flagging inaccurate data across multiple clinical trials.

Immusoft, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today the formation of its Scientific Advisory Board (SAB) composed of world-renowned experts to provide external scientific review and high-level counsel on the Company’s research and development programs.

MYND Life Sciences Inc. a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce it has expanded its intellectual property portfolio for diseases of the central nervous system, including methods for treating or delaying Alzheimer’s disease and related forms of dementia.

Revolo Biotherapeutics announced today the approval of an investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA) to evaluate ‘1104.

SCYNEXIS, Inc. today announced that it will present a commercial launch update for its recently FDA-approved drug, BREXAFEMME® (ibrexafungerp tablets).